PSCA

PSCA

Target · Cell-surface glycoprotein

PSCA Prostate stem cell antigen

PSCA (prostate stem cell antigen) is a glycosylphosphatidylinositol-anchored cell membrane glycoprotein of the LY6/PLAUR domain containing group. It may modulate nicotinic acetylcholine receptor activity and is up-regulated in a large proportion of prostate cancers; lncPSCA is a recorded alias. Browse Assay Genie's current range of PSCA research reagents below, or read on for the biology behind the target.

Cell membrane glycoproteinGPI-anchored, LY6/PLAUR groupUp-regulated in prostate cancer
114 aa
Protein length
~12 kDa
Molecular weight
8q24.3
Gene locus
LY6/PLAUR
Protein family
Target information

What is PSCA (prostate stem cell antigen)?

PSCA may act as a modulator of nicotinic acetylcholine receptor (nAChR) activity. In vitro, it inhibits nicotine-induced signalling, probably involving nAChRs that contain alpha-3:beta-2 or alpha-7 subunits. The protein is anchored to the outer face of the cell membrane through a glycosylphosphatidylinositol (GPI) linkage, which places it at the cell surface where it can influence receptor-mediated signalling.

The PSCA gene encodes a cell membrane glycoprotein and belongs to the HGNC gene group LY6/PLAUR domain containing. As the name suggests, expression is high in the prostate, but the NCBI Gene summary also reports expression in the bladder, placenta, colon, kidney and stomach. The mouse ortholog is designated Psca. Alternative splicing of the gene results in multiple transcript variants.

PSCA is of particular interest in cancer research. The gene is up-regulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas. The gene includes a polymorphism that creates an upstream start codon in some individuals, and this variant is thought to be associated with risk for certain gastric and bladder cancers. Together with its surface localisation, these features make PSCA a frequently studied marker in epithelial tumour biology.

Prostate cancer research

PSCA is up-regulated in a large proportion of prostate cancers, making it a relevant marker for studying prostate tumour biology.

Bladder and pancreatic cancers

The gene is also detected in cancers of the bladder and pancreas, supporting comparative studies across tumour types.

Gastric cancer genetics

A polymorphism creating an upstream start codon is thought to be associated with risk for certain gastric and bladder cancers.

Nicotinic receptor signalling

PSCA may modulate nAChR activity and inhibits nicotine-induced signalling in vitro, linking it to cholinergic signalling studies.

Background

PSCA frequently asked questions

What does PSCA do?

PSCA may act as a modulator of nicotinic acetylcholine receptor (nAChR) activity. In vitro it inhibits nicotine-induced signalling, probably involving alpha-3:beta-2- or alpha-7-containing nAChRs. It is a GPI-anchored glycoprotein located at the cell membrane.

What other names and transcript forms does PSCA have?

The official name is prostate stem cell antigen, and lncPSCA is a listed alias. The NCBI Gene summary notes that alternative splicing of the PSCA gene produces multiple transcript variants, so researchers should consider which form is relevant to their work.

Is PSCA linked to disease, and is it conserved in mouse?

PSCA is up-regulated in many prostate cancers and detected in bladder and pancreatic cancers. A polymorphism is thought to be associated with risk for certain gastric and bladder cancers. The mouse ortholog is Psca; check the datasheet of any product for its validated reactivity.

Explore

Related targets

Nicotinic receptor subunits, LY6/PLAUR family members and prostate cancer markers related to PSCA.

Gene and protein annotations from HGNC, NCBI Gene and UniProt O43653; product specifications from Assay Genie datasheets.

PSCA Product listing